Product Information
ABACAVIR-LAMIVUDINE 600-300 MG is a generic product labeled by Cipla USA Inc., priced at $1.4836 per EA under NDC 69097036202. Its NADAC has been published 490 times since May 17, 2017.
FDA first approved this application on Mar 28, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
600; 300 mg/1; mg/1
Manufacturer
Cipla USA Inc.NDC
69097036202
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ABACAVIR SULFATE; LAMIVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA091144FDA Approved
3/28/2017
TE Code
AB
On Market Since
3/28/2017
Pharmacological Classes
Price Statistics
The NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has been published 490 times since May 17, 2017, and over the history we have for it it has declined 92.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.4836 per EA |
|---|---|
| All-time high | $20.2246 (Jun 14, 2017) |
| All-time low | $1.2091 (Nov 22, 2023) |
| 52-week high | $1.5668 |
| 52-week low | $1.2621 |
| Median price | $2.1389 |
| Average price | $2.5873 |
| Largest weekly change | -66.0% (Jun 21, 2017) |
| Weeks tracked | 490 |
| Tracking since | May 17, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Abacavir and lamivudine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Abacavir and lamivudine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ABACAVIR-LAMIVUDINE 600-300 MG?
The current National Average Drug Acquisition Cost (NADAC) for ABACAVIR-LAMIVUDINE 600-300 MG, manufactured by Cipla USA Inc., is $1.4836 per EA (NDC 69097036202), effective Sep 30, 2026.
How has the price of ABACAVIR-LAMIVUDINE 600-300 MG changed over time?
Over the history we have for it, the NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has declined 92.7%. It has been tracked across 490 weekly CMS publications since May 17, 2017.
What are the highest and lowest recorded NADAC prices for ABACAVIR-LAMIVUDINE 600-300 MG?
Since May 17, 2017, the NADAC for ABACAVIR-LAMIVUDINE 600-300 MG has ranged from a low of $1.2091 (Nov 22, 2023) to a high of $20.2246 (Jun 14, 2017), with a median of $2.1389 per EA.
Are there cheaper alternatives to ABACAVIR-LAMIVUDINE 600-300 MG?
No other NADAC-published product currently shares the active ingredient and strength of ABACAVIR-LAMIVUDINE 600-300 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ABACAVIR-LAMIVUDINE 600-300 MG?
ABACAVIR-LAMIVUDINE 600-300 MG (NDC 69097036202) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.